Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656071 · ClinicalTrials.gov registry record
Retrospective Postoperative ARDS Study at Vanderbilt University
A clinical trial of ARDS, sponsored by Vanderbilt University.
- Completed
- Registry status
- 89
- Enrollment target
- 1
- Study location
NCT00656071: Completed study of ARDS, sponsored by Vanderbilt University.
NCT00656071 is a study of ARDS that has completed, run by Vanderbilt University. The registered enrollment target is 89 participants, below the 581-participant average among 14 other ARDS trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00656071, a study of ARDS, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
By examining the intraoperative anesthetic characteristics of patients who developed ARDS postoperatively, we hope to identify variables which have a positive or negative association on the development of ARDS.
Conditions Studied
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-08 |
What the finished NCT00656071 record still lists
NCT00656071 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 581-participant average among 14 other ARDS trials with a reported enrollment target (85% lower).
The record links to 1 condition, with ARDS appearing as the primary indexed condition, and to 0 interventions.
NCT00656071 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00656071 about?
NCT00656071 is a clinical study titled "Retrospective Postoperative ARDS Study at Vanderbilt University". By examining the intraoperative anesthetic characteristics of patients who developed ARDS postoperatively, we hope to identify variables which have a positive or negative association on the development of ARDS.
What is the current status of trial NCT00656071?
This trial is currently completed. The enrollment target is 89 participants. The study started on 2007-10. Estimated completion is 2008-08.
What conditions does trial NCT00656071 study?
This clinical trial studies the following conditions: ARDS.
Who is sponsoring clinical trial NCT00656071?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00656071 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ARDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00656071's enrollment target sits among peer trials
89 10th of 14 higher than 5 of 14 other ARDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ARDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
RECRUITING · Phase 2
-
The APS Phenotyping Study
RECRUITING
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
RECRUITING · Phase 2
-
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
RECRUITING · Phase 3
-
Ventilatory Parameters in Predicting Outcomes in ARDS Patients
RECRUITING
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia